Table 1 Baseline characteristics of IMN patients
From: New risk score for predicting progression of membranous nephropathy
All | |
|---|---|
Follow-up time (m) | 38.73 ± 19.35 |
Age (years) | 56 (15–83) |
Female (%) | 209 (47.61%) |
Albumin (g/l) | 23 (8–43) |
Proteinuria (g/24 h) | 3.98 (1.5–22.98) |
eGFR (ml/min/1.73 m2) | 100.31 (12.81–155.98) |
Microscopic hematuria (%) | 260 (59.22%) |
Triglyceride (mmol/l) | 2.35 (0.70–10.92) |
Cholesterol (mmol/l) | 7.17 (1.84–16.71) |
Uric acid (μmol/l) | 357.03 ± 83.38 |
Serum PLA2R antibody (RU/l) | 26.54 (0.52–1040.18) |
Pathology | |
LM-stages I and II (%) | 348 (79.27%) |
LM- ≥ 50% tubulointerstitial lesions (%) | 15 (3.42%) |
IF-PLA2R positive staining (%) | 80/94 (85.11%) |
IF-IgG1 positive (%) | 95/112 (84.82%) |
IF-IgG4 positive (%) | 104/112 (92.86%) |
Primary outcomes (%) | 36 (8.20%) |
Renal function progression (%)a | 24 (5.47%) |
Death (%) | 9 (2.05%) |
ESRD (%) | 3 (0.68%) |